Farms.com Home   News

Seaboard Reports Strong Q2 Results on Strength of Pork and Turkey Segments

Seaboard Corporation delivered solid second quarter financial results, driven by improved margins in its pork operations and positive returns from its investment in Butterball, a leading turkey producer.

The company reported net sales of nearly $2.5 billion for the quarter ending June 28, 2025, representing a 12% increase compared to the same period last year. Net income rose significantly to $102 million, up from $61 million a year earlier.

Pork Segment Posts $32 Million Operating Income Increase

The pork segment was a key driver of the improved performance. Operating income rose by $32 million during the quarter, fueled by stronger margins on pork products and live hog sales. Despite modest declines in overall sales volume, the company achieved improved profitability by capitalizing on more favorable market conditions and managing production costs effectively.

Butterball Delivers $17 Million in Equity Earnings

Seaboard’s 52.5% non-controlling interest in Butterball also contributed to the bottom line. The turkey company reported $17 million in net income for the quarter, reflecting increased demand and higher sales of turkey products. This investment continues to provide meaningful returns and enhances Seaboard’s position in the broader protein space.

Diversified Model Supports Long-Term Stability

In addition to its pork and turkey segments, Seaboard operates in various sectors including marine, energy, commodities, and food processing. This diversification has allowed the company to remain resilient in the face of changing global market dynamics. The strong quarterly results highlight the value of integrated operations and targeted investment strategies.

Click here to see more...

Trending Video

How Aurora Pharmaceutical Became a Leader in Animal Health

Video: How Aurora Pharmaceutical Became a Leader in Animal Health

Dr. Michael Strobel, Founder and CEO of Aurora Pharmaceutical, discusses the company's remarkable journey from a veterinarian-led startup to a leading developer and manufacturer of animal health solutions.

In this exclusive interview, Dr. Strobel shares how Aurora Pharmaceutical was built around a simple but powerful mission: putting customers, producers, veterinarians, pet owners, and patients first. Learn how the company has grown by focusing on high-quality, science-backed, and cost-effective solutions for livestock, companion animals, and human health markets.

Discover how Aurora's commitment to innovation, affordability, and customer service continues to drive its expansion across swine, cattle, poultry, equine, companion animal, and human health sectors. Dr. Strobel also discusses the importance of understanding real-world challenges facing producers and veterinarians and how Aurora develops practical solutions that improve animal health while supporting producer profitability. Aurora's veterinarian-founded approach, commitment to American manufacturing, and focus on delivering value have helped establish the company as a trusted partner throughout the animal health industry.